Merck & Co Inc

NYSE:MRK   12:15:01 PM EDT
86.45
+0.61 (+0.71%)
Products

Merck Receives Fast Track Designation From FDA For An Investigational Anticoagulant Therapy

Published: 08/23/2022 11:03 GMT
Merck & Co Inc (MRK) - Merck Receives Fast Track Designation From the U.S. FDA for Mk-2060, an Investigational Anticoagulant Therapy.
Merck & Co Inc - Phase 2 Study of Mk-2060 Currently Ongoing in People With End-stage Renal Disease Receiving Hemodialysis.